OBJECTIVE: This study aimed to determine the safety and feasibility of robotic radical trachelectomy and bilateral pelvic lymphadenectomy. We also describe our surgical technique. METHODS: This is a retrospective review of all patients who underwent robotic radical trachelectomy and bilateral pelvic lymphadenectomy from October 2008 to May 2009. We analyzed our data to evaluate the safety and feasibility of this surgery. RESULTS: This analysis included 4 patients with early-stage squamous cell carcinoma of the cervix. The median body mass index was 27.1 kg/m(2) (range, 22.7 to 39.1). Three patients had stage IA2 adenocarcinoma; 1 patient had stage IA1 adenocarcinoma with lymph-vascular space invasion. The median operative time was 339.5 min (range, 245 to 416). The median console time was 282.5 min (range, 217 to 338). The median estimated blood loss was 62.5 ml (range, 50 to 75). There were no conversions to laparotomy. There were no intraoperative complications. No patient required blood transfusion. The median length of hospital stay was 1.5 days (range, 1 to 2). One patient experienced a postoperative complication, transient left lower extremity sensory neuropathy. No patient had residual tumor in the trachelectomy specimen, and no patient underwent adjuvant therapy. The median number of pelvic lymph nodes removed was 20 (range, 18 to 27). The median time to a successful voiding trial was 8 days (range, 7 to 9). The median follow-up was 105 days (range, 82 to 217). There were no recurrences. CONCLUSION: Robotic radical trachelectomy and bilateral pelvic lymphadenectomy is feasible and safe and should be considered for patients desiring fertility-sparing surgery.
OBJECTIVE: This study aimed to determine the safety and feasibility of robotic radical trachelectomy and bilateral pelvic lymphadenectomy. We also describe our surgical technique. METHODS: This is a retrospective review of all patients who underwent robotic radical trachelectomy and bilateral pelvic lymphadenectomy from October 2008 to May 2009. We analyzed our data to evaluate the safety and feasibility of this surgery. RESULTS: This analysis included 4 patients with early-stage squamous cell carcinoma of the cervix. The median body mass index was 27.1 kg/m(2) (range, 22.7 to 39.1). Three patients had stage IA2 adenocarcinoma; 1 patient had stage IA1 adenocarcinoma with lymph-vascular space invasion. The median operative time was 339.5 min (range, 245 to 416). The median console time was 282.5 min (range, 217 to 338). The median estimated blood loss was 62.5 ml (range, 50 to 75). There were no conversions to laparotomy. There were no intraoperative complications. No patient required blood transfusion. The median length of hospital stay was 1.5 days (range, 1 to 2). One patient experienced a postoperative complication, transient left lower extremity sensory neuropathy. No patient had residual tumor in the trachelectomy specimen, and no patient underwent adjuvant therapy. The median number of pelvic lymph nodes removed was 20 (range, 18 to 27). The median time to a successful voiding trial was 8 days (range, 7 to 9). The median follow-up was 105 days (range, 82 to 217). There were no recurrences. CONCLUSION: Robotic radical trachelectomy and bilateral pelvic lymphadenectomy is feasible and safe and should be considered for patients desiring fertility-sparing surgery.
Authors: Gloria Salvo; Pedro T Ramirez; Mario Leitao; David Cibula; Christina Fotopoulou; Ali Kucukmetin; Gabriel Rendon; Myriam Perrotta; Reitan Ribeiro; Marcelo Vieira; Glauco Baiocchi; Henrik Falconer; Jan Persson; Xiaohua Wu; Mihai Emil Căpilna; Nicolae Ioanid; Berit Jul Mosgaard; Igor Berlev; Dilyara Kaidarova; Alexander Babatunde Olawaiye; Kaijiang Liu; Silvana Pedra Nobre; Roman Kocian; Srdjan Saso; Stuart Rundle; Florencia Noll; Audrey Tieko Tsunoda; Kolbrun Palsdottir; Xiaoqi Li; Elena Ulrikh; Zhijun Hu; Rene Pareja Journal: Int J Gynecol Cancer Date: 2019-02-13 Impact factor: 3.437
Authors: Alpa M Nick; Michael M Frumovitz; Pamela T Soliman; Kathleen M Schmeler; Pedro T Ramirez Journal: Gynecol Oncol Date: 2011-10-27 Impact factor: 5.482
Authors: Ramez N Eskander; Leslie M Randall; Michael L Berman; Krishnansu S Tewari; Philip J Disaia; Robert E Bristow Journal: Am J Obstet Gynecol Date: 2011-03-16 Impact factor: 8.661
Authors: Ashlee L Smith; Michael Frumovitz; Kathleen M Schmeler; Ricardo dos Reis; Alpa M Nick; Robert L Coleman; Pedro T Ramirez Journal: Gynecol Oncol Date: 2010-08-12 Impact factor: 5.482
Authors: Ali Hassan Hamed; Marguerite K Shepard; Dean D T Maglinte; Sandra Ding; Giuseppe Del Priore Journal: JSLS Date: 2012 Oct-Dec Impact factor: 2.172